About: Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy
Creator	Gisondi, Paolo Piaserico, Stefano Cazzaniga, · Naldi, ·
source	Medline; PMC
abstract	covid:017ea51c4755cfd6ae26d8445eb44f6bf48c7ee9#abstract
has issue date	2020-08-18(xsd:dateTime)
bibo:doi	10.1007/s40257-020-00552-w
bibo:pmid	32812188
has license	no-cc
sha1sum (hex)	017ea51c4755cfd6ae26d8445eb44f6bf48c7ee9
schema:url	https://doi.org/10.1007/s40257-020-00552-w
resource representing a document's title	Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy
has PubMed Central identifier	PMC7433672
has PubMed identifier	32812188
schema:publication	Am J Clin Dermatol
resource representing a document's body	covid:017ea51c4755cfd6ae26d8445eb44f6bf48c7ee9#body_text
is schema:about of	named entity 'Psoriasis' named entity 'Abbvie' named entity 'COVID-19' named entity 'IL-12' named entity 'incidence rate' named entity '95% CI' named entity 'general population' named entity 'incidence rate' named entity 'COVID-19' named entity 'COVID-19' named entity 'pneumonia' named entity 'COVID-19' named entity '95% CI' named entity '95% CI' named entity 'incidence rate' named entity '1.10' named entity '95% CI' named entity 'general population' named entity 'Pfizer' named entity 'Northern Italy' named entity 'COVID-19' named entity 'etanercept' named entity 'TNF inhibitors' named entity '95% CI' named entity '12.2' named entity 'biologic therapy' named entity 'COVID-19' named entity '1 June' named entity 'Almirall' named entity 'COVID-19' named entity 'life-threatening' named entity 'general population' named entity '95% CI' named entity 'COVID-19' named entity 'Sandoz' named entity 'COVID-19' named entity 'Merck Sharp & Dohme' named entity 'Celgene' named entity 'sulfasalazine' named entity 'Abbvie' named entity 'COVID-19 infection' named entity 'Novartis' named entity 'ustekinumab' named entity '7.5' named entity 'general population' named entity 'comorbidities' named entity 'guselkumab' named entity 'follow-up' named entity 'funding source' named entity '95% CI' named entity 'Almirall' named entity '13.8' named entity 'COVID-19' named entity '11.5' named entity 'COVID-19' named entity 'Celgene' named entity 'hypertension' named entity 'Abbvie' named entity 'Novartis' named entity 'COVID-19' named entity 'biologics' named entity '10.4' named entity 'general population' named entity 'Pfizer' named entity 'COVID-19' named entity 'Celgene' named entity 'inflammatory bowel disease' named entity 'biologics' named entity 'secukinumab' named entity 'COVID-19' named entity 'pneumonia' named entity 'pneumonia' named entity '95% CI' named entity 'diabetes mellitus' named entity 'Veneto Region' named entity 'COVID-19' named entity '1.2' named entity 'Novartis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software